Option chain shows key data for Nuo Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nuo Therapeutics.

Nuo Therapeutics (OTC:AURX) Stock, Option Chain

Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

AURX

The Dow Jones closed lower by around 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Container Store Group And 2 Other Penny Stocks Insiders Are Buying

QEGY

TCON

Gold futures traded slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Stocks Under $3 Insiders Are Aggressively Buying

NUO THERAPEUTICS INC NEW by Nuo Therapeutics, Inc.

Nuo Therapeutics Inc

The Dow Jones closed lower by around 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Container Store Group </h3>
<ul>
<li>The Trade: The Container Store Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcs#NYSE">TCS</a>) CFO Jeffrey A Miller <a href="https://www.benzinga.com/quote/TCS/analyst-ratings"> acquired a total of 3,860 shares </a> an average price of $2.60. To acquire these shares, it cost around $10,023.</li>
<li>What&rsquo;s Happening: Container Store reported worse-than-expected first-quarter financial results..</li>
<li>What Container Store Group Does: The Container Store Group Inc is a U.S. based specialty retailer of storage and organization products and solutions. It offers a collection of multifunctional and customizable storage and organization solutions.</li>
</ul>
<h3>Nuo Therapeutics </h3>
<ul>
<li>The Trade: Nuo Therapeutics, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/aurx#OTC">AURX</a>) 10% owner Charles E Sheedy <a href="https://www.benzinga.com/quote/AURX/analyst-ratings"> acquired a total of 62,500 shares </a> at an average price of $2.00. The insider spent around $125,000.</li>
<li>What&rsquo;s Happening: The company&rsquo;s stock declined 22% over the past month.</li>
<li>What Nuo Therapeutics Does: Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company&#39;s commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing.</li>
</ul>
<h3>RENN Fund</h3>
<ul>
<li>The Trade: RENN Fund, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcg#NYSE">RCG</a>) CEO and President Murray Stahl <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 419 shares </a> at an average price of $1.85. To acquire these shares, it cost around $775.</li>
<li>What&rsquo;s Happening: RENN Fund shares have gained around 2% since the start of the year.</li>
<li>What RENN Fund Does: RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed with the objective of providing long-term capital appreciation by investing substantially in privately placed convertible and equity securities of emerging growth companies traded on the United States securities exchanges.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/08/33573526/wall-streets-most-accurate-analysts-say-hold-these-3-consumer-stocks-delivering-high-dividend-yields"> Wall Street&#39;s Most Accurate Analysts Say Hold These 3 Consumer Stocks Delivering High-Dividend Yields </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Gold futures traded slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h2>TRACON Pharmaceuticals </h2>
<ul>
<li>The Trade: TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) President and CEO Charles Theuer <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,000 shares </a> at an average price of $1.97. To acquire these shares, it cost $9.85 thousand.</li>
<li>What&rsquo;s Happening: TRACON Pharmaceuticals posted a Q4 net loss of $7.7 million.</li>
<li>What TRACON Pharmaceuticals Does: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States.</li>
</ul>
<h2>Standard BioTools </h2>
<ul>
<li>The Trade: Standard BioTools Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lab#NASDAQ">LAB</a>) 10% owner Edward David Johnson <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 400,000 shares </a> at an average price of $2.69. The insider spent around $1.08 million to buy those shares.</li>
<li>What&rsquo;s Happening: Standard BioTools is expected to report first quarter 2022 financial results on Thursday, May 5, 2022.</li>
<li>What Standard BioTools Does: Standard BioTools Inc, formerly Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics.</li>
</ul>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/22/05/26962166/executives-buy-more-than-90m-of-4-stocks">Also check this: Executives Buy More Than $90M Of 4 Stocks </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>.
<h2>Quantum Energy </h2>
<ul>
<li>The Trade: Quantum Energy, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/qegy#OTC">QEGY</a>) CFO William Westbrook <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 44,000 shares </a> at an average price of $0.30. To acquire these shares, it cost around $13.16 thousand.</li>
<li>What&rsquo;s Happening: The company&rsquo;s shares have dropped 15% since the start of the year.</li>
<li>What Quantum Energy Does: Quantum Energy Inc is a development stage diversified holding company with an emphasis on land holdings, refinery, and fuel distribution. Geographically it holds a presence in the United States and Canada.</li>
</ul>
<h2>Nuo Therapeutics </h2>
<ul>
<li>The Trade: Nuo Therapeutics, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/aurx#OTC">AURX</a>) 10% owner Charles E Sheedy <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 804,868 shares </a> at an average price of $1.00. The insider spent $804.87 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: The company recently entered into an agreement to acquire the Reward Project, located just seven miles from the Company&#39;s Bullfrog Project in Nevada.</li>
<li>What Nuo Therapeutics Does: Nuo Therapeutics Inc is a biomedical company that pioneers edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.</li>
</ul>

IPOs

Audeo Oncology Files to Withdraw S-1 for IPO

An announcement from Nuo Therapeutics (AURX) is now available. Nuo Therapeutics, Inc. has announced a delay in filing its Annual Report on Form 10-...

Comments

Nuo Therapeutics

Nuo Therapeutics (AURX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga